First Trust Advisors LP Trims Stake in United Therapeutics Corporation $UTHR

First Trust Advisors LP reduced its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 1.6% in the third quarter, according to its most recent filing with the SEC. The fund owned 300,495 shares of the biotechnology company’s stock after selling 5,017 shares during the period. First Trust Advisors LP owned about 0.70% of United Therapeutics worth $125,970,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. WealthCollab LLC raised its stake in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. boosted its holdings in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the period. Wilmington Savings Fund Society FSB grew its stake in United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares in the last quarter. Abich Financial Wealth Management LLC bought a new position in United Therapeutics in the third quarter worth approximately $44,000. Finally, Geneos Wealth Management Inc. increased its holdings in United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 85 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on UTHR. Royal Bank Of Canada upped their target price on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Oppenheimer raised their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Wells Fargo & Company upped their price objective on shares of United Therapeutics from $423.00 to $466.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 26th. Finally, Bank of America reissued a “neutral” rating on shares of United Therapeutics in a research report on Wednesday, February 25th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $539.00.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $478.16 on Monday. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $537.19. The firm has a market capitalization of $20.96 billion, a price-to-earnings ratio of 17.14, a PEG ratio of 1.72 and a beta of 0.84. The stock’s 50-day simple moving average is $482.51 and its 200-day simple moving average is $454.28.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating the consensus estimate of $6.78 by $0.92. The firm had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. United Therapeutics’s revenue was up 7.4% on a year-over-year basis. During the same period last year, the firm posted $6.19 EPS. As a group, equities analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: UBS raised its price target on UTHR from $655 to $705 and kept a Buy rating — a notable analyst endorsement implying material upside that could attract buyers. Read More.
• Neutral Sentiment: Multiple sell‑side firms have recently increased targets and reiterated Buy/outperform views (Oppenheimer, HC Wainwright, TD Cowen); consensus remains a “Moderate Buy” with a mid‑range price target, supporting a constructive medium‑term thesis. Read More.
• Negative Sentiment: A wave of insider selling this week is pressuring sentiment: CEO Martine Rothblatt sold 9,500 shares (~$4.65M), and several directors/executives (Ray Kurzweil, Paul Mahon, Tommy G. Thompson and others) also sold blocks at roughly $483–$490 per share. These large, concentrated disposals can prompt near‑term weakness even if insiders retain stakes. Read More. Read More.

Insider Activity

In other news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction on Monday, December 15th. The shares were sold at an average price of $496.30, for a total transaction of $11,166,750.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 329,684 shares of company stock valued at $160,260,377 over the last three months. Company insiders own 10.30% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.